Supplementary Table S1. NICE HTA assessment of pazopanib

General information	
Indication	Pazopanib is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease
Manufacturer	GlaxoSmithKline
Type of HTA	Single Technology Appraisal—STA (NICE TA 215)
Final Guidance (date)	Recommended (February 2011)
Appraisal Committee	Appraisal Committee C
Evidence Review/Assessment Group	Aberdeen HTA group
Clinical effectiveness—treatment-naive subpopulation	
Trial comparator	Best supportive care (BSC)
Sample size (experimental/control)	N = 233 (155/78)
Study efficacy outcomes	Primary endpoint: PFS Secondary endpoint: OS
Median PFS	Pazopanib: 11.1 months BSC: 2.8 months (Δ = 8.3 months) • HR = 0.40 (95% CI 0.27–0.60)
OS—interim (ITT analysis)	Pazopanib: NR BSC: NR (Δ = NA) • HR = 0.74 (95% CI 0.47–1.15)

BSC = best supportive care; CI = confidence interval; HR = hazard ratio; HTA = health technology assessment; TT = intent to treat; NA = not available; NR = not reported; NICE = National Institute for Health and Care Excellence; PFS = progression-free survival; OS = overall survival.